INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events
Item 8.01. Other Events.
On December1, 2016, GlaxoSmithKline plc (GSK) and Innoviva,Inc.
(Innoviva) announced the Japanese Ministry of Health, Labor and
Welfares approval of RELVAR ELLIPTA (fluticasone furoate /
vilanterol 100/25 mcg), the first once-daily ICS/LABA medication
for chronic obstructive pulmonary disease (COPD), for the relief
of various symptoms with COPD (chronic bronchitis, pulmonary
emphysema) (in the case where concurrent use of inhaled
corticosteroid and long-acting inhaled beta2 agonist is
required). RELVAR ELLIPTA has been developed under the LABA
collaboration agreement between Glaxo Group Limited and Innoviva.
Item9.01. Financial Statements and
Exhibits.
(d)Exhibits
|
99.1 |
Press Release dated December1, 2016 |
About INNOVIVA, INC. (NASDAQ:INVA)
Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD). INNOVIVA, INC. (NASDAQ:INVA) Recent Trading Information
INNOVIVA, INC. (NASDAQ:INVA) closed its last trading session down -0.13 at 10.21 with 1,821,854 shares trading hands.